In This Section
Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
The new AUC for differentiated thyroid cancer (DTC) addresses several clinical scenarios for nuclear medicine in evaluation and treatment. To improve utilization and guide providers to use nuclear medicine for DTC in a more appropriate way, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American Academy of Family Physicians (AAFP), the American College of Nuclear Medicine (ACNM), the European Association of Nuclear Medicine (EANM), the American Thyroid Association (ATA), the American Association of Endocrine Surgeons (AAES), the American Head and Neck Society (AHNS), the American Association of Clinical Endocrinologists (AACE), and the Endocrine Society have collaboratively developed criteria for the appropriate use of this imaging technology to aid in the use of radiopharmaceuticals for diagnosis and therapy in patients with DTC. This AUC has been endorsed by the American College of Nuclear Medicine (ACNM), the American Association of Endocrine Surgeons (AAES), the American Association of Clinical Endocrinologists (AACE), American Head & Neck Society (AHNS), the American Thyroid Association (ATA), and the European Association of Nuclear Medicine (EANM).
SNMMI assembled an autonomous DTC Workgroup consisting of experts in the field of nuclear medicine including imaging specialists, family physicians, surgeons and endocrinologists to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the DTC Workgroup put together, which they used to make their recommendations for clinical use.
To view the development process, please click the following link: SNMMI AUC Development Process.